Antiviral phosphodiamide prodrugs of tenofovir
US10745428B2 · kind B2 · utility
1Cited by
8References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 5, 2016 |
| Grant date | Aug 18, 2020 |
| Priority date | — |
| Expiry date | Dec 5, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.